Milk-based dietary supplement lowers blood pressure in hypertensive patients

Blood PressureWashington, May 17: A milk-based dietary supplement reduces blood pressure in hypertensive patients, according to results of two new clinical trials.

Presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans, the studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptideĀ® Dietary Supplement ) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study, confirmed the safety and efficacy of AmealPeptideĀ® for patients with Stage I and Stage II hypertension.

The AHEAD II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6 mmHg for the active group after 6 weeks of treatment. The change was both statistically and clinically significant.

According to JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), just a 2 mmHg reduction in systolic blood pressure results in a 6 pc reduction in mortality due to stroke and a 4 pc reduction in mortality due to coronary heart disease (CHD).

Results of the PROBE study showed AmealPeptideĀ® to have a dose dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6 mmHg (Ā± 8.7) in the 75 mg a day group and also a significant reduction in 24-hr systolic blood pressure in the same group of 6.2 mmHg (Ā± 8.4) from the baseline after 8 weeks of treatment. A lower dose of 5 mg a day of AmealPeptideĀ® also showed blood pressure lowering effect.

ā€œItā€™s very exciting to see blood pressure reductions achieved by the food derived substance, AmealPeptideĀ®ā€ stated Joel Neutel, MD, Associate Clinical Professor of Medicine at the University of California, Irvine and a specialist in clinical hypertension of the American Society of Hypertension.

ā€œWith hypertension and prehypertension on the rise, physicians and patients need as many effective tools as possible for the management of this condition,ā€ he added.

The AHEAD II study enrolled 81 newly diagnosed stage I and stage II hypertensives. All subjects had a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. Fifty-two received 75 mg of AmealPeptideĀ® twice a day for 6 weeks, while 29 received a placebo.

The PROBE study enrolled 59 diagnosed stage I and stage II hypertensives who were not taking any antihypertensive medications or who were uncontrolled on antihypertensive therapy. All subjects had a mean seated systolic blood pressure between 150 mmHg and 179 mmHg and a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial. All enrolled received AmealPeptideĀ® (5mg, 15mg, 50mg, 75mg a day or 75mg twice a day) or placebo.

"Calpis takes pride in conducting research that holds up under serious scientific scrutiny," said Craig Tillman, Vice President of Sales & Marketing, Calpis USA, Inc. (ANI)

Diseases: 
General: 
Regions: